IL18 and neoplasm: When tumor volume reached 75–100 mm3, 15 mg/kg of RMP-IL-18mutE2, RMP-IL-18mutE4, RMP-IL-18mutE6 (1,000,000-fold IL-18 attenuation) or 15 mg/kg αPD-1, were administered on day 0 and 4.